Tumor necrosis factor (TNF) is a key protein that plays a vital role in the regulation of immune cells. It is a proinflammatory cytokine produced primarily by activated monocytes or macrophages.
TNF is synthesized as a transmembrane protein (tmTNF) and split by the matrix metalloproteinase TNF converting enzyme to soluble TNF.
TNF is considered a significant player in inflammatory reactions. Several Clinical studies have proved that the level of TNF is significantly high in patients suffering from autoimmune diseases like ankylosing spondylitis, rheumatoid arthritis, Crohn’s disease, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, and refractory asthma.
TNF drug class is the most successful drug classes in the industry across the globe. This success has led pharmaceutical companies to develop therapeutics, which aims at inhibiting the overexpression of TNF. The use of TNF inhibitors in every above-mentioned clinical condition has been found to provide excellent therapeutic efficacy with slightest side effects, thus making them universal leaders in the pain management, autoimmune disorder, and inflammatory therapeutic segment. Among the blockbuster drugs in the market, 50% belong to this class.
Etanercept (Enbrel), Adalimumab (Humira), Certolizumab, and Golimumab (Simponi) are the key therapeutics that make up the global TNF inhibitors market.
The extensive application of these approved drugs for various autoimmune conditions ensures continuous market growth in the coming decade. Around 45% of TNF inhibitors in the pipeline are evaluated for the treatment of rheumatoid arthritis.
The pipeline analysis report on TNF inhibitors has identified that equal percentage of studies are going on in phase 1, phase 2 and phase 3 clinical trials. Most of the pipeline molecules are under clinical trial studies. Celgene has produced 2 molecules that are TNF-alpha inhibitor and are in the market. Fibromun of Philogen is in Phase 3. P27600from Piramal is in Phase 2, CYT-6091of CytImmune is in Phase 1 stage of development. Debio 0512 of Neovacs, Debiopharm is in the preclinical stage of development. Apart from developing biologics, biosimilars are also being developed to combat the need of the products.
High frequency of chronic conditions such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, plaque psoriasis, & others, provision of structured reimbursement policies, continuous research activities in developing target-based biologics and growing inclination towards cost-efficient biosimilars in developing economies contribute to the remunerative growth of this market.
A global rise in elderly population and an increase in the prevalence of immune disorders like psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel disease are key factors that drive the TNF inhibitors market.
Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!